30 August 2021 | News
Approves Sofwave's state-of-the-art Synchronous Ultrasound Parallel Beam technology
Image credit: istock
Israel-based startup Sofwave Medical has received approval from the Korean Ministry of Foods and Drug Safety (MFDS) to market Sofwave™ its proprietary next-generation Synchronous Ultrasound Parallel Beam technology SUPERB™ for reducing the appearance of fine lines and wrinkles while also revitalizing the skin.
"MFDS approval of Sofwave™ is another major step in our international product growth strategy for this novel non-invasive wrinkle reduction ultrasound treatment," said Sofwave's Chief Executive Officer Louis Scafuri. "As one of the world's fastest-growing medical aesthetic regions, the Asia Pacific market is an important one for Sofwave."
Sofwave's state-of-the-art Synchronous Ultrasound Parallel Beam technology SUPERB™ addresses the growing demand for non-invasive treatments that deliver noticeable wrinkle reduction.
The device's seven cooled transducers are directly coupled to the epidermis, creating a unique 3D array of volumetric thermal zones that deliver parallel energy simultaneously, heating precisely at the right depth in the mid-dermis to improve the overall appearance.
A single Sofwave treatment reduces facial wrinkles in a fast 30 to 45 minute non-invasive treatment with no interruption to a patient's daily routine or post-treatment discomfort.